← Browse by Condition
Medical Condition

smoldering multiple myeloma

Total Trials
2
Recruiting Now
2
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for smoldering multiple myeloma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — smoldering multiple myeloma Clinical Trials

How many clinical trials are currently recruiting for smoldering multiple myeloma?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for smoldering multiple myeloma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for smoldering multiple myeloma?
smoldering multiple myeloma research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a smoldering multiple myeloma clinical trial?
Eligibility criteria for smoldering multiple myeloma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Dana-Farber Cancer Institute 1 trial
Memorial Sloan Kettering Cancer Center 1 trial

Recruiting Clinical Trials

NCT02269592
Recruiting
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Enrollment
10,000 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT05640843
Recruiting
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Enrollment
180 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →

Related Conditions

monoclonal gammopathy of undetermined significance mgus (1) myelodysplastic syndromes (1) hematological malignancies (1) b cell malignancy low grade (1) myelodysplastic syndrome with low grade lesions (1) igg monoclonal gammopathy of uncertain significance (1) waldenstrom macroglobulinemia (1) monoclonal gammopathy of undetermined significance (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology